Tribunal directs AO to re-quantify disallowances & remove transfer pricing adjustments

The Tribunal partially allowed the appeals by directing the Assessing Officer to re-quantify disallowances under Section 14A and delete certain adjustments related to transfer pricing issues. The Tribunal emphasized adherence to legal principles and established precedents in its decision.

---

---

Issues Involved:
1. Disallowance under Section 14A of the Income Tax Act.
2. Disallowance under Section 35(2AB) of the Income Tax Act.
3. Transfer pricing adjustment regarding interest-free loans to associated enterprises (AEs).
4. Transfer pricing adjustment regarding subscription to share capital of AEs treated as deemed loans.
5. Transfer pricing adjustment regarding outstanding balances with AEs.

Issue-wise Detailed Analysis:

1. Disallowance under Section 14A of the Income Tax Act:
The Assessing Officer (AO) disallowed Rs. 3,36,78,061 under Section 14A read with Rule 8D, which was sustained by the CIT(A). The AO did not record any satisfaction for invoking Rule 8D, and the disallowance was made mechanically. The Tribunal observed that 99% of the dividend income was from group companies, and no expenditure was incurred for earning this income. The Tribunal directed the AO to re-quantify the disallowance only from general administrative expenses and exclude investments on which no exempt income was earned, following the decision in ACIT v. Vireet Investments Private Limited.

2. Disallowance under Section 35(2AB) of the Income Tax Act:
The AO disallowed Rs. 49,24,573 incurred on clinical trials outside the R&D facilities, which was claimed under Section 35(2AB). The CIT(A) sustained the disallowance. The Tribunal, following the decision in CIT v. Cadila Healthcare Ltd., allowed the alternative claim under Section 37(1) as the expenditure was revenue in nature and not capital.

3. Transfer Pricing Adjustment Regarding Interest-Free Loans to AEs:
The AO, based on the Transfer Pricing Officer (TPO)'s recommendation, made an adjustment of Rs. 1,75,70,642 for interest-free loans to Reliance Life Sciences Inc. (RLSI) by applying a 6% interest rate. The Tribunal observed that the loan was optionally convertible into equity and was converted into equity before the due date. The Tribunal held that no interest should be imputed as the transaction was quasi-capital and not a routine loan. The Tribunal also noted that benchmarking against another controlled transaction was inappropriate.

4. Transfer Pricing Adjustment Regarding Subscription to Share Capital of AEs Treated as Deemed Loans:
The AO treated the subscription to share capital of RLSI and RLSBV as deemed loans and charged interest, which was sustained by the CIT(A). The Tribunal held that recharacterization of the transaction was not permissible, following the decisions in DIT v. Besix Kier Dabhol SA and Pr CIT v. Aegis Ltd. The Tribunal directed the AO to delete the adjustment.

5. Transfer Pricing Adjustment Regarding Outstanding Balances with AEs:
The AO treated outstanding balances with Reliance Genemedix (RGMX) as loans and charged interest at 12% p.a., which was sustained by the CIT(A). The Tribunal observed that the assessee had a consistent policy of not charging interest on receivables/payables from both AEs and non-AEs. Following the decisions in CIT v. Indo American Jewellery Ltd. and CIT v. Livingstones, the Tribunal held that no interest should be charged on outstanding balances with AEs and directed the AO to delete the adjustment.

Conclusion:
The Tribunal allowed the appeals partly, directing the AO to re-quantify disallowances and delete certain adjustments, emphasizing adherence to legal principles and established precedents.

---